Article Text

Download PDFPDF
PARTNER randomised controlled trial
In people with severe aortic stenosis unsuitable for surgery transcatheter aortic valve implantation reduces 1-year mortality compared with standard care
  1. Ronak Rajani
  1. Cedars-Sinai Medical Center, Los Angeles, CA, USA
  1. Correspondence to Ronak Rajani
    8700 Beverly Blvd, Los Angeles, CA 90048, USA; dr.r.rajani{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on:


Aortic stenosis is a common condition occurring in 2–4% of adults over the age of 65 years. This prevalence increases with age and it is estimated that up to 2.9% of adults between the ages of 75 and 86 years have severe aortic stenosis.1 Although the annual mortality for patients with asymptomatic stenosis is low (1%),2 once symptoms develop, the prognosis is poor. The mean survival after the onset of heart failure is 11 months, after syncope 27 months and after angina 45 months.3

Current guidelines recommend surgery for patients with severe aortic stenosis who have symptoms or in asymptomatic patients with a left ventricular ejection fraction <50%.4 However, up to 30% of patients with symptoms have numerous concurrent comorbidities and are considered to be too high risk for surgical intervention. Historically, these patients have been managed medically or occasionally with aortic valve balloon valvuloplasty. Transcatheter aortic valve implantation (TAVI) has now emerged as a viable alternative. Since its first description by Cribier and colleagues in 2002,5 in excess of 8000 procedures have been performed worldwide. Although the initial results have been encouraging in terms of procedural success, and both short- and medium-term mortality, this has been at the expense of a relative high 30-day or inhospital mortality of 10–22%. There has …

View Full Text


  • Competing interests RR is currently funded by the American College of Cardiology and the British Cardiovascular Society.